Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Göteborg, Sweden.
Wallenberg Laboratory for Cardiovascular and Metabolic Research, Institute of Medicine, University of Gothenburg, Göteborg, Sweden.
Sci Rep. 2023 Jan 21;13(1):1192. doi: 10.1038/s41598-023-27941-5.
The association between type 2 diabetes (T2D) and the development of cardiac arrhythmias and conduction disturbances has not been extensively studied. Arrhythmia was defined as atrial fibrillation and flutter (AF/AFl), ventricular tachycardia (VT) and ventricular fibrillation (VF), and conduction abnormality as sinus node disease (SND), atrioventricular (AV) block or pacemaker implantation, and intraventricular conduction blocks (IVCB). Incidence rates and Cox regression were used to compare outcomes, and to assess optimal levels for cardiometabolic risk factors and risk associated with multifactorial risk factor control (i.e., HbA1c, LDL-C, systolic blood pressure (SBP), BMI and eGFR), between patients with versus without T2D. The analyses included data from 617,000 patients with T2D and 2,303,391 matched controls. Patients with diabetes and the general population demonstrated a gradual increase in rates for cardiac conduction abnormalities and virtually all age-groups for AF/AFI showed increased incidence during follow-up. For patients with versus without T2D, risks for cardiac arrhythmias were higher, including for AF/AFl (HR 1.17, 95% CI 1.16-1.18), the composite of SND, AV-block or pacemaker implantation (HR 1.40, 95% CI 1.37-1.43), IVCB (HR 1.23, 95% CI 1.18-1.28) and VT/VF (HR 1.08, 95% CI 1.04-1.13). For patients with T2D who had selected cardiometabolic risk factors within target ranges, compared with controls, risk of arrythmia and conduction abnormalities for T2D vs not were: AF/AFl (HR 1.09, 95% CI 1.05-1.14), the composite of SND, AV-block or pacemaker implantation (HR 1.06, 95% CI 0.94-1.18), IVCB (HR 0.80, 95% CI 0.60-0.98), and for VT/VF (HR 0.97, 95% CI 0.80-1.17). Cox models showed a linear risk increase for SBP and BMI, while eGFR showed a U-shaped association. Individuals with T2D had a higher risk of arrhythmias and conduction abnormalities than controls, but excess risk associated with T2D was virtually not evident among patients with T2D with all risk factors within target range. BMI, SBP and eGFR displayed significant associations with outcomes among patients with T2D.
2 型糖尿病(T2D)与心律失常和传导障碍的发展之间的关系尚未得到广泛研究。心律失常定义为心房颤动和扑动(AF/AFl)、室性心动过速(VT)和心室颤动(VF),传导异常为窦房结疾病(SND)、房室(AV)阻滞或起搏器植入以及室内传导阻滞(IVCB)。使用发病率和 Cox 回归来比较结局,并评估心脏代谢危险因素和多因素危险因素控制(即 HbA1c、LDL-C、收缩压(SBP)、BMI 和 eGFR)的最佳水平,比较有和无 T2D 的患者之间的结局。分析包括 617000 例 T2D 患者和 2303391 例匹配对照的数据。患有糖尿病的患者和普通人群的心脏传导异常发生率逐渐增加,几乎所有年龄组的 AF/AFI 在随访期间的发病率都有所增加。与无 T2D 的患者相比,心律失常的风险更高,包括 AF/AFl(HR 1.17,95%CI 1.16-1.18)、SND、AV 阻滞或起搏器植入的复合症(HR 1.40,95%CI 1.37-1.43)、IVCB(HR 1.23,95%CI 1.18-1.28)和 VT/VF(HR 1.08,95%CI 1.04-1.13)。对于 T2D 患者中选择心脏代谢风险因素在目标范围内的患者,与对照组相比,T2D 患者的心律失常和传导异常风险为 T2D 与非 T2D 相比:AF/AFl(HR 1.09,95%CI 1.05-1.14)、SND、AV 阻滞或起搏器植入的复合症(HR 1.06,95%CI 0.94-1.18)、IVCB(HR 0.80,95%CI 0.60-0.98)和 VT/VF(HR 0.97,95%CI 0.80-1.17)。Cox 模型显示 SBP 和 BMI 的风险呈线性增加,而 eGFR 则呈 U 型关联。与对照组相比,T2D 患者心律失常和传导异常的风险更高,但在 T2D 患者中,所有危险因素均在目标范围内的患者中,T2D 相关的额外风险几乎不存在。BMI、SBP 和 eGFR 在 T2D 患者的结局中显示出显著的相关性。